Omega Therapeutics Net Tangible Assets Over Time
| OMGA Stock | USD 0.86 0.07 8.86% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Omega Therapeutics Performance and Omega Therapeutics Correlation. Omega |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share 0.114 | Quarterly Revenue Growth 1.812 | Return On Assets (0.25) | Return On Equity (1.29) |
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Tangible Assets Analysis
Compare Omega Therapeutics and related stocks such as Pmv Pharmaceuticals, Eliem Therapeutics, and MediciNova Net Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMVP | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (46.1 M) | (70.5 M) | 359.1 M | 308.6 M | 246 M | 282.9 M | 175.4 M |
| MNOV | 13.9 M | 13.9 M | 5.3 M | 15.8 M | 12.4 M | 23.2 M | 24.9 M | 29 M | 63.5 M | 65.3 M | 61.7 M | 74.1 M | 60.6 M | 69.7 M | 41.2 M |
| PHVS | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 5 M | 18.6 M | 95.6 M | 205 M | 149.3 M | 171.6 M | 104.1 M |
| PEPG | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | 3.9 M | (6.4 M) | (32.1 M) | 179.6 M | 206.6 M | 216.9 M |
| OLMA | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (10.6 M) | 338.1 M | 284.6 M | 197.5 M | 227.2 M | 176.7 M |
| NVCT | (10.0) | (10.0) | (10.0) | (10.0) | (10.0) | (10.0) | (10.0) | (10.0) | (10.0) | (10.0) | (10.0) | (11 M) | 14.2 M | 16.4 M | 17.2 M |
| LRMR | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 2.9 M | (694 K) | 89.7 M | 64.4 M | 110.9 M | 127.5 M | 133.9 M |
| CNTA | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 491.6 M | 336.2 M | 386.6 M | 304.6 M |
| OBIO | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (48.5 M) | (71.2 M) | (71.2 M) | (64.1 M) | (67.3 M) |
| AVTE | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (13.3 M) | 172.4 M | 172.4 M | 198.3 M | 208.2 M |
| ELVN | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (42.9 M) | (42.9 M) | (38.6 M) | (40.5 M) |
| MLTX | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 107.9 M | 48.9 M | 44 M | 62.7 M |
| GPCR | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (22.5 M) | (64.7 M) | (115.1 M) | (103.6 M) | (108.8 M) |
| CMPX | (84.8 M) | (84.8 M) | (84.8 M) | (84.8 M) | (84.8 M) | (84.8 M) | (84.8 M) | (84.8 M) | (84.8 M) | (118.6 M) | 39.9 M | 140.1 M | 181.6 M | 208.9 M | 219.3 M |
| MLYS | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (3.6 M) | (22.9 M) | (52.3 M) | (47 M) | (44.7 M) |
| CVKD | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5 M) | (5.2 M) |
Omega Therapeutics and related stocks such as Pmv Pharmaceuticals, Eliem Therapeutics, and MediciNova Net Tangible Assets description
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.My Equities
My Current Equities and Potential Positions
| Omega Therapeutics | OMGA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.86
Check out Omega Therapeutics Performance and Omega Therapeutics Correlation. For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Omega Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.